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TNF/Cachectin, a monokine released from macrophages after exposure to endo-
toxin, is an important mediator ofthe hosts' response to Gram-negative bacteremia
(1) and is one of the agents responsible for cachexia observed in chronic infection
and metastatic cancer (2). TNF also mediates characteristic features ofthe inflam-
matory response(3), and as such, is functionally relatedto other cytokines, including
the IFNs, ILs, and CSFs. The inflammatory response is often associated with the
local production ofproteolytic enzymes and cytotoxic factors, leading to cell death,
extracellular matrix degradation, fibrin deposition, and subsequently the replace-
ment of functional tissue by scar tissue. TNF, as well as IL-1, have been shown to
evoke the release of collagenase and prostaglandin E2 from human synovial cells
and dermal fibroblasts (4).
Coagulation disorders frequently observed after exposure to endotoxin or TNF
suggestthatTNFmayalso affect the hemostatic balance. Inthis regard, recent studies
have demonstrated that TNF induces tissue factor and inhibits thrombomodulin
expressionon the surface ofendothelialcells (5, 6). An effect onthe fibrinolytic system
has received relatively little attention. The fibrinolytic system is not only required
for the removal of blood clots within the vascular system (natural thrombolysis),
butalso forthedegradation ofextravascular fibrin deposits (7). Theprincipal fibrino-
lytic enzyme is plasmin, which is generated from its zymogen plasminogen by one
of two genetically distinct plasminogen activators (PA)t: urokinase-type PA (u-PA)
and tissue-type PA (t-PA) (8). The rate of plasmin formation is modulated by two
specific and fast-acting plasminogen activatorinhibitors (PAIs) : PAI-1 (9) and PAI-2
(10). PAI-1 is found inplasma, platelets, and in the conditioned mediaofendothelial
and other cultured cells (11). PAI-2 is found in monocytes and granulocytes and is
predominantly an intracellular nonglycosylated protein (12). A glycosylated form
ofPAI-2 is found in low concentrations in the plasma of pregnant women (13) and
in the culture supernatants of monocytes/macrophages and the U-937 monocyte-
like cell line (14). The physiological role ofPAI-2 is still unclear, however, the tissue
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distribution of this inhibitor suggests that it may function locally during inflamma-
tion and wound healing.
To explore a possible effect of TNF on the fibrinolytic enzyme system, we have
used the human fibrosarcoma cell line HT1080, which constitutively expresses both
PAs and both PAIs (15). Here, we provide evidence that TNF suppresses constitu-
tively secreted fibrinolytic activity of HT-1080 cells, and that this effect is mediated
by the simultaneous transcriptional induction of both plasminogen activator inhibi-
tors in concert with suppression of t-PA gene expression.
Materials and Methods
Cell Culture and Harvesting ofMedia.
￿
HT-1080 cells (originally derived from a fibrosarcoma
arising adjacent to the acetabulum of a 35-yr-old caucasian male) were purchased from the
American Type Culture Collection (Rockville, MD). Cells were cultured to confluency in
150-cm2 culture flasks (Corning Glass Works, Corning, NY) in 40 ml DME containing 2
mM glutamine and 10% heat-inactivated FCS (Gibco Laboratories, Paisley, UK). Before
the start of an experiment, cells were maintained overnight at 37°C in serum-free DME.
To start an experiment, medium was replaced with fresh serum-free DME with or without
human rTNF (Biogen, Geneva, Switzerland). Cells were subsequently maintained for var-
ious times up to 48 h.
Activity Assay.
￿
Plasminogen-dependent fibrinolytic activity in conditioned medium was
determined by the Fibrin plate assay (16).
Preparation of Cellular Extracts.
￿
To quantify cell-associated u-PA, t-PA, PAI-1, and PAI-2,
cells were harvested after various incubation times by trypsinization, washed in 20 ml ofPBS,
centrifuged, and then disrupted by adding 5 ml of0.5% ice-cold NP-40 lysis buffer as previ-
ously described (15). Nuclei were sedimented, and the supernatant containing the cellular
extract was removed and stored at -30°C until further use.
Antigen Determinations.
￿
Secreted and cell-associated u-PA, PAIR, and PAI-2 antigen levels
were determined by RIA as previously described (13). t-PA antigen was determined using
an ELISA kit (Biopool imulyse 5 t-PA; Biopool, Umea, Sweden), according to manufacturers
instructions.
DNA Probes.
￿
The probes used were the 1,000-bp Pst 1 insert of human PAIR cDNA (17)
(kindly provided by Dr. David Loskutoff, Scripps Clinic and Research Foundation, LaJolla,
CA); the Eco RI insert of pPAI J7, harboring 1,900 by of the human PAI-2 cDNA (18); the
Bgl II fragment ofpPA 11 4B cDNA harboring 1,948 by of the human t-PA cDNA (19); the
Eco Rl fragment of pUK 0321 harboring 1,023 by of the human u-PA cDNA (15). Mouse
0-actin cDNA (20) was a generous gift from Dr. Stefania Petrucco, Swiss Institute for Cancer
Research, Epalinges, Switzerland; a human genomic PAI-2 clone (chPAI-2 8) was isolated
from a human Charon 4A gene library using the labeled Eco RI insert of pPAI J7 (above).
The authenticity ofthe clone was established by sequencing the first two exons. Metallothionein
Ila: Plasmid pH MT113 (21), was a kind gift from Dr. Rob Richards, Howard Florey Insti-
tute, Melbourne, Australia. Labeling of all probes with a s2P dATP was performed by the
random priming technique (22). For the "Run-on"transcription assay, probes were linearized
and fixed to nitrocellulose as previously described (23). 2 ug of DNA was applied per slot.
Northern Blot Analysis.
￿
The isolation ofmRNA from cultured cells and agarose gel (0.9%)
electrophoresis of mRNA in the presence of 20% formaldehyde followed by Northern blot
transfer (25) was performed as previously described (24), but using Gene Screen Plus mem-
brane (New England Nuclear, Boston, MA) in place of nitrocellulose filter paper. Hybridiza-
tion conditions and processing of filters were performed as described (24) .
Run-on Transcription Assay.
￿
The methods used were essentially as originally described by
Greenberg and Ziff (23) and modified by Medcalf et al. (15). Mean nuclei count for each
sample was ti7 x 106 . Filter strips containing cDNA slots were hybridized simultaneously
for 36 h at 65°C, then washed, RNase treated, air dried, and exposed to X-ray film for up
to 10 d.MEDCALF ET AL.
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Densitometry.
￿
Densitometric analysis of transcription and mRNA signals on autoradio-
grams was performed using a densitometer (Ultrascan XL model 2222; LKB-Pharmacia,
Dfibendorf, Switzerland). All calculations were expressed relative to an arbitrary value of
1 assigned to the intensity of the signal obtained for each sample at time point 0.
Results
Fibrinolytic activity constitutively present in HT-1080 cell-conditioned medium
was suppressed by TNF in a dose-dependent fashion. Over 99% suppression oc-
curred with 2.5 ng/ml TNF, while no fibrinolytic activity could be detected with
25 or 250 ng/ml TNF (Table I). To determine the mechanism by which TNF was
exerting this effect, we used specific antigen assays to determine the relative changes
in secreted andcell-associated u-PA, t-PA, PAI-1, andPAI-2 in the same conditioned
medium (Table I). From these data, it was evident that the loss of fibrinolytic ac-
tivity was primarily due to an increase of secreted PAI-1, and to a lesser extent, to
secreted PAI-2. As with monocytes/macrophages, >90% of PAI-2 is cell associated
(12, 14). In this system, intracellular PAI-2 increased 11-fold to 1,900 ng/106 cells.
Levels of u-PA, the predominant PA in this cell line, were unaffected, whereaslevels
of t-PA antigen (a relatively minor component in this system) were decreased.
Using cDNA probes, we investigated whether the antigen changes were a reflec-
tion of the steady state mRNA levels. Northern blot analysis indicated that, in a
dose-dependent manner, TNF increased PAI-2 mRNA, as well as the 3.4- and 2.4-
bp species (17) of PAI-1 mRNA, while at the same time suppressing t-PA mRNA
(Fig. 1). To determinethe time course of this effect, mRNA was extracted from cells
afterexposure to TNF (50 ng/ml) for various times up to 48 h. Densitometric anal-
ysis of the Northern blot autoradiograms demonstrated that TNF evoked a sustained
16-fold and 100-fold increase in PAI-1 and PAI-2 mRNA, respectively, commencing
between 4 and 8 h. The suppression of t-PA mRNA followed a similar time course
(Fig. 2). Constitutive expression ofPAM andPAI-2 mRNA was restored by removing
TNF from the culture medium showing the reversibility of the effect (Fig. 3).
Steady-state mRNA levels maychange as a result of variations ofmRNA stability,
gene transcription rates, or a combination of both effects. To determine whether
the time-dependent changes in mRNA quantity were the result ofa change in gene
template activity, we assayed relative changes in PAI-1, PAI-2, and t-PA gene tran-
scription rates in isolated nuclei usingthe "Run-on" transcription assay (Fig. 4). The
results of these experiments demonstrate that the increase in the observed mRNA
levels was due to a 4- and 20-fold increase in PAM and PAI-2 gene transcription,
respectively, as determined by densitometric analysis of the autoradiograms. This
induction was noticeable after 2 h for PAI-2 and after 8 h for PAI-1. For both, max-
imal levels were attained after 48 h of exposure to TNF. Modulation of t-PA gene
transcription could notbe assessed with accuracy due to the relatively low basal level
of constitutive t-PA gene template activity.
Discussion
The data presented in this report indicate that TNRCachectin induces gene tran-
scription of PAI-1 and PAI-2, and simultaneously suppresses gene expression of t-
PA. The consequent suppression of fibrinolytic activity would therefore appear to
be primarily due to an increase of secreted PAI-1, and to a lesser extent, to secreted754 TUMOR NECROSIS FACTOR AND FIBRINOLYSIS
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FIGURE 1 .
￿
Dose-dependent modulation ofPAI-1, PAI-
2, and t-PAmRNA byTHE mRNA prepared from HT
1080 cells treated for 24 h with 0, 2 .5, 25, or 250 ng/ml
human TNF was assessed by Northern blot analysis .
Dexamethasone (Sigma ChemicalCo., St . Louis, MC,
[Dex, 10' M]), was added to cells as a control for in-
duction ofPAI-1 and t-PAmRNA (15) and suppression
of u-PA mRNA (24) . Relative changes of PAI-1, PAI-2,
t-PA, and u-PA were determined by hybridization to
random primer labeled PAI-1, PAI-2, t-PA, and u-PA
cDNA probes of similar specific activity. Successive
hybridizations ofeach probe to the same membrane are
illustrated . Arrows to the left represent the position of
the 28 S and 18 S ribosomal RNA markers .
FIGURE 2 .
￿
Time course ofPAI-1 and PAI-
2 mRNA accumulation and suppression
of t-PAmRNA byTNF in HT-1080 cells .
mRNA was prepared from nontreated (0
h) cells or from cells treated with 50 ng/ml
TNF for 2, 4, 8, 24, and 48 h . Northern
blot analysis of PAI-1, PAI-2, and t-PA
mRNA was performed as described in the
legend to Fig . 1 . Successive hybridizations
of each probe to the same membrane are
illustrated .
PAI-2 . As with monocytes/macrophages, >90% of PAI-2 is cell associated (12, 14) .
In this system, cell-associated PAI-2 increased 11-fold to 1,900 ng/106 cells . Libera-
tion of these large amounts of PAI-2, either by cell death, or by an as yet unknown
mechanism, would further contribute to the inhibition of fibrinolytic activity .
Whether the effects ofTNF seen here in fibrosarcoma cells are tissue specific or
FIGURE 3 .
￿
Reversibility ofthe effect ofTNF HT
1080 cells, cultured as described in the legend to
Fig . 1, were treated for 24 h in eitherDME alone
or DME containing 50 ng/ml human TNF.
Medium was removed and the cell monolayer
washed withDME before a further 30-h incuba-
tion in eitherDME or 50 ng/mlTNF (see below) .
mRNA was then extracted and assessed for PAI-
1 and PAI-2 mRNA by Northern blot analysis
as described in the legend to Fig . 1 . Successive
hybridizations ofeach probe to the same filter are
illustrated . (Lane 1) 24-h DME ; (lane 2) 24-h
TNF ; (lane 3) 24-hDME followed by 30 hDME ;
(lane 4) 24-hDME followed by 30 hTNF; (lane
5) 24-hTNF followed by 30 hDME ; (lane 6) 24-
5 TNF followed by a further 30 h TNF.756
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FIGURE 4 . Time course of
TNF-induced modulation of
PAI-1 andPAI-2 gene transcrip-
tion . HT1080 cell nuclei were
prepared from nontreated (0 h)
cells and from cells treated for
2, 4, 8, 24, or 48 h with 50 ng/ml
TNF . Elongation and labeling
ofinitiated RNA transcripts in
isolated nuclei and hybridiza-
tion to immobilized cDNA or
genomic slot blots (see below)
was performed following a
modification of the originally
described "Run-on" transcrip-
tion assay (see Materials and
Methods) . Exposure times were
chosen to visually optimize the
signals present .
general remains to be determined . A recent report, however, has demonstrated that
TNF induces PAI-1 mRNA and suppresses secreted t-PA antigen in bovine aortic
endothelial cells (26) . Endothelial cells are key components of local hemostasis and
fibroblasts play a pivotal role in wound healing and tissue repair. Thus, it seems
that TNF released from macrophages under normal circumstances may lead to a
localized suppression of the fibrinolytic enzyme system and, thereby, stabilize the
fibrin deposited at the wound site. However, the systemic increase of TNF, which
occurs in Gram-negative septicemia, has pathogenic consequences . The integrity
of the vascular system is not only compromised by thehypofibrinolytic state induced
by TNF, but also by the induction of procoagulant activity (tissue factor) on the
surface of the endothelial cell (5, 6) . The concomitant induction of both PAIs and
the suppression of t-PA in endothelial cells would stabilize microthrombi in the
microvascular system leading to anoxia and subsequent tissue necrosis . A recent
study has provided morphological evidence that thrombus formation is indeed as-
sociated with the anti-tumor activity ofTNF (27) . It is conceivable that agents de-
signed to activate the fibrinolytic system (such as PAs), or to inactivate the PAIs,
could be used to counteract the hemostatic complications induced by TNF .
TNF has previously been shown to increase mRNA levels of IL-1 (28) and the
histocompatibility antigens, HLA-A,B (29), and suppressmRNA levels of a number
oflipogenic genes in adipocytes (30) . PAN and PAI-2 represent the first geneswhere
an effect of TNF on gene template activity was directly demonstrated .
TheHT1080 cell line provides amodel system foran investigation ofTNRmediated
modulation of gene transcription . Isolation and characterization of the PAI gene
promoters will allow the identification ofTNF modulated cis-acting elements and
the respective trans-acting factors required for the induction of PAI-1 andPAI-2 bio-
synthesis . Whereas PAI-1 has been shownto be transcriptionally regulated by dexa-
methasone in HT-1080 cells (15) and PAI-2 by a tumor-promoting phorbol ester in
U-937 histiocytic lymphoma cells (18), TNF is the only known compound that in-
duces both inhibitors simultaneously in one cell type . The reversibility of theTNFMEDCALF ET AL.
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effect should encourage the search for TNF receptor antagonists with possible anti-
inflammatory properties.
Summary
Human rTNF/Cachectin was shown to stimulate gene transcription ofplasminogen
activator inhibitor (PA1)-1 and PAI-2, and simultaneously suppress constitutive gene
expression oftissue-type plasminogen activator (t-PA) in human fibrosarcoma cells.
We propose that a TNFmediated reprogramming of gene transcription induces,
in appropriate target cells, an anti-fibrinolytic state, which may cooperate with the
induction of procoagulant activity (tissue factor) to stabilize the fibrin deposits com-
monly found in inflamed tissue. PAI genes also provide a model system for a study
of the molecular pathways underlying TNF-mediated signal transduction.
We are indebted to Marlies Ruegg and Elizabeth Cousin for theirexpert technical assistance;
Dr. Max Hausermann (LKB-Pharmacia) for densitometric analysis of the autoradiograms;
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during the course of this work and for critical reading of the manuscript.
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